Latest News about Atai Life Sciences
Recent news which mentions Atai Life Sciences
Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies
October 04, 2024
From Benzinga
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
September 12, 2024
From Benzinga
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
September 05, 2024
From Benzinga
Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant
August 14, 2024
Tickers
ATAI
From Benzinga
Atai Life Sciences: Capital Raise, Share Options, Cathy Wood And More On Biotech Psychedelics Leader
July 07, 2022
Tickers
ATAI
From Benzinga
ATAI Life Sciences Present A "New Recipe For Success" At The Psychedelic Capital Conference
April 29, 2022
Tickers
ATAI
From Benzinga
From Benzinga
Are Psychedelics Starting to Emerge as Legitimate Therapies?
January 19, 2022
From Stock Gumshoe
National Institute on Drug Abuse Will Test Ibogaine For Addiction Treatment As Drug Deaths Crest 100,000
December 08, 2021
From Benzinga
New York's Horizons Psychedelic Conference Highlights Big Donations In The Growing Industry
December 07, 2021
From Benzinga
Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass Pathways
November 29, 2021
From Benzinga
This Psychedelics Stock Was Up More Than 20% Last Week, Outperforming Tesla, Nvidia and GameStop
November 02, 2021
From Benzinga
Tickers
TC
From TechCrunch
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.